Clinical Trial Detail

NCT ID NCT02770014
Title Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

lung non-small cell carcinoma

Therapies

Erlotinib

Age Groups: adult senior

No variant requirements are available.